Pharma

Your Article Summary

See Latest Articles

Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
Active Biotech, 06/02/09

This pivotal Phase III study evaluates the efficacy and safety of ANYARA in combination with interferon-alfa compared to interferon-alfa alone, in patients with advanced renal cell cancer. The primary clinical efficacy parameter is overall survival. Final survival data for ANYARA will be analyzed after 384 events and the current estimate is that these will be presented by the end of 2010/beginning of 2011.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

Position statement of the Portuguese Society of Nephrology on the clinical use of biotechnological drugs in renal patients
Portuguese Journal of Nephrology and Hypertension, 10/12/09

Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
Pharmaceutical Technology, 10/14/09

See All of Biotechnology

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials